Iacobellis G, et al. - Researchers conducted this 24‐week, randomized, double‐blind, placebo‐controlled clinical trial to analyze the impacts of dapagliflozin, a selective sodium‐glucose cotransporter 2 inhibitor, on epicardial adipose tissue (EAT) thickness in patients with type 2 diabetes and obesity. Participants in the study were T2DM patients (n = 100) with BMI ≥ 27 kg/m² and a hemoglobin A1c level ≤ 8% on metformin monotherapy. Participants in the study were randomly assigned to two groups to receive additional dapagliflozin up to 10 mg once daily or to remain on metformin up to 1,000 mg twice daily. No statistically significant association was found between EAT and body weight changes. Findings suggested that dapagliflozin induces a rapid and significant reduction in EAT which may be independent of weight loss.